StreetInsider.com News Articles

TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking

Mon, 05 Oct 2026 03:05:00 -0400

VIVI Cap Smart transforms injectable medication protection into a connected health-data layer, enabling patients, caregivers and digital-health platforms to capture medication-use, temperature and adherence signals.

Toronto, Ontario--(Newsfile Corp. - October 5, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology company transforming the storage, protection and management of temperature-sensitive medications, is pleased to announce that its VIVI Cap Smart™ platform now supports connectivity with Apple Health and Google Fit, advancing the Company's strategy to make injectable medication use visible within leading health and wellness ecosystems.

VIVI Cap Smart™ is TempraMed's connected temperature-protection device

TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking

Mon, 05 Oct 2026 03:05:00 -0400

VIVI Cap Smart™ is TempraMed's connected temperature-protection device

TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking

Mon, 05 Oct 2026 03:05:00 -0400

VIVI Cap Smart™ is TempraMed's connected temperature-protection device

TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking

Mon, 05 Oct 2026 03:05:00 -0400

VIVI Cap Smart™ is TempraMed's connected temperature-protection device

TempraMed closes $1.18M private placement on CSE

Wed, 30 Sep 2026 18:02:09 -0400

TempraMed Technologies Ltd. (CSE: VIVI) has closed a non-brokered private placement, raising gross aggregate proceeds of $1,177,940 through the issuance of convertible debentures and units, according to a press release dated September 30, 2026.

The company issued $600,000 in principal amount of unsecured convertible debentures and 1,155,880 units. Each unit consists of one common share and one warrant, with each warrant exercisable to purchase one additional common share at C$1.00 on or before March 30, 2028.

The convertible debentures carry an interest rate of 10% per annum, calculated monthly and payable quarterly in cash. They mature on September 30, 2027, and may

TempraMed Technologies Ltd. Announces Closing of Private Placement

Wed, 30 Sep 2026 18:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), is pleased to announce that, further to its September 23, 2026 and September 28, 2026 news releases, it has closed its non-brokered private placement (the "Offering") of unsecured convertible debentures of the Company (each, a "Convertible Debenture") and units (each, a "Unit"). The Company issued $600,000 of principal amount of Convertible Debentures and 1,155,880 Units under the Offering for gross aggregate proceeds of $1,177,940.

Each Unit issued under the Offering consists of one common share in the capital of the Company (each, a

TempraMed Technologies Ltd. Announces Closing of Private Placement

Wed, 30 Sep 2026 18:00:00 -0400

Each Unit issued under the Offering consists of one common share in the capital of the Company (each, a

TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus

Tue, 29 Sep 2026 03:05:00 -0400

Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors

Highlights:

LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.

Toronto, Ontario--(Newsfile Corp. - September

TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus

Tue, 29 Sep 2026 03:05:00 -0400

Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors

Highlights:

LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.

Toronto, Ontario--(Newsfile Corp. - September

TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus

Tue, 29 Sep 2026 03:05:00 -0400

Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors

Highlights:

LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.

Toronto, Ontario--(Newsfile Corp. - September

TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus

Tue, 29 Sep 2026 03:05:00 -0400

Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors

Highlights:

LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.
Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement.
CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.

Toronto, Ontario--(Newsfile Corp. - September

TempraMed Announces Upsize to Offering

Mon, 28 Sep 2026 17:49:00 -0400

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-brokered private placement (the "Offering") previously announced on Wednesday, September 23, 2026. The Upsized Offering will include up to C$600,000 in unsecured convertible debentures (each, a "Debenture") and up to C$1,000,000 in units (each, a "Unit") for aggregate gross proceeds of up to C$1,600,000.

Each Unit will consist of one common share of the

TempraMed Announces Upsize to Offering

Mon, 28 Sep 2026 17:49:00 -0400

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

Each Unit will consist of one common share of the

TempraMed expands Latin American distribution and plans C$1M raise

Thu, 24 Sep 2026 02:57:15 -0400

TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) has amended its exclusive distribution agreement with TEM Consulting International S.A., extending the arrangement beyond Panama to Argentina, Venezuela, Colombia and Costa Rica, and adding the VIVI Med product to the covered portfolio.

The amended agreement also includes an additional commercial order from TEM, which TempraMed expects to fulfill by the end of September 2026. The initial extended-territory framework contemplates minimum unit commitments across the added countries, with additional annual commitments tied to exclusivity. TEM is responsible for obtaining all required governmental licenses, registrations, import authorizations and other regulatory approvals in each

TempraMed expands Latin American distribution and plans C$1M raise

Thu, 24 Sep 2026 02:57:15 -0400

TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement

Thu, 24 Sep 2026 02:55:00 -0400

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations

Highlights

TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.
The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™.
TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026.
Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity.
Once required registrations are completed, TempraMed products are

TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement

Thu, 24 Sep 2026 02:55:00 -0400

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations
Highlights
TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.
The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™.
TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026.
Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity.
Once required registrations are completed, TempraMed products are

TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement

Thu, 24 Sep 2026 02:55:00 -0400

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations
Highlights
TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.
The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™.
TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026.
Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity.
Once required registrations are completed, TempraMed products are

TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement

Thu, 24 Sep 2026 02:55:00 -0400

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations
Highlights
TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.
The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™.
TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026.
Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity.
Once required registrations are completed, TempraMed products are

TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana

Wed, 23 Sep 2026 03:05:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a major U.S. health insurer.
About TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops

TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana

Wed, 23 Sep 2026 03:05:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a major U.S. health insurer.
About TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops

TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana

Wed, 23 Sep 2026 03:05:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a major U.S. health insurer.
About TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops

TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana

Wed, 23 Sep 2026 03:05:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a major U.S. health insurer.
About TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops

TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue

Fri, 18 Sep 2026 16:45:00 -0400

Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance.
The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in TempraMed's history. August 2026 sales reached approximately US$403,000, representing the Company's second-highest

TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue

Fri, 18 Sep 2026 16:45:00 -0400

Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance.
The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in TempraMed's history. August 2026 sales reached approximately US$403,000, representing the Company's second-highest